CRYSTAL DORRIETY: Open Payments
NPI 1184961310 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,123 in 63 payments from 17 companies in 2025. Trend: 2023 $554 · 2024 $1,000 · 2025 $1,123
Food & beverage: $1,123
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $178 |
| Novartis Pharmaceuticals Corporation | 7 | $175 |
| AstraZeneca Pharmaceuticals LP | 7 | $141 |
| Novo Nordisk Inc | 15 | $139 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $112 |
| Sumitomo Pharma America, Inc. | 5 | $89 |
| GlaxoSmithKline, LLC. | 3 | $51 |
| Lilly USA, LLC | 3 | $47 |
| PFIZER INC. | 2 | $43 |
| Seqirus USA Inc | 1 | $26 |
Products named: CUVITRU, Kerendia, GEMTESA, Ozempic, Rhapsido, AIRSUPRA, Rybelsus, BREZTRI.
Industry payments across AL — which companies pay providers there.
